Arcalyst
(Rilonacept)Phase 2Protein / enzyme
Rilonacept is used to treat rare inflammatory conditions, including cryopyrin-associated periodic syndromes (CAPS) and gout attacks. It works by blocking proteins in the body that cause inflammation and pain.[1] Arcalyst is currently being investigated across 5 indications[3], with its most advanced program in Phase 2.[1]
Arcalyst is one of 106 small molecule programs targeting Immune System Disease. It is currently in Phase 2.
5
Indications
24
Total Trials
1
Active Trials
105
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
55 competitors in Immune System Disease
#DrugCompanyPhaseTrials
1Tecfidera
BiogenApproved
Otezla
AmgenApproved
Thalomid
Bristol-Myers SquibbApproved
Cellcept
RocheApproved
Trexall
Jazz PharmaceuticalsApproved
Medrol
PfizerApproved
Crestor
AstraZenecaApproved
Avelox
BayerApproved
Neoral
NovartisApproved
Sotyktu
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Gout4 trials
Show 1 more trial
Systemic Juvenile Idiopathic Arthritis2 trials
Chronic Kidney Disease2 trials
Urticaria1 trial
Cold Contact Urticaria Treatment With Rilonacept
Completed·—·Phase 2·NCT02171416·20 enrolled
14 more indications
Safety and Efficacy1 trial
Cryopyrin-Associated Periodic Syndrome1 trial
Pericarditis1 trial
Interleukin1 trial
Rilonacept for Deficiency of the Interleukin-1 Receptor Antagonist (DIRA)
Completed·NNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)·Phase 2·NCT01801449·6 enrolled
Effectiveness1 trial
Hepatitis1 trial
Muckle-Wells syndrome1 trial
Safety and Tolerability of Rilonacept in Muckle-Wells Syndrome (MWS) or Schnitzler Syndrome (SchS)
Completed·—·Phase 2·NCT01045772·10 enrolled
Systemic Sclerosis1 trial
IL1-TRAP, Rilonacept, in Systemic Sclerosis
Completed·—·Phase 1/2·NCT01538719·24 enrolled
Regulatory
FDA Approval Timeline[4]
Feb 27, 2008
ARCALYST
BLA BLA125249
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Rilonacept. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details